Short Interest in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Declines By 8.5%

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) was the recipient of a large drop in short interest in December. As of December 31st, there was short interest totalling 2,150,000 shares, a drop of 8.5% from the December 15th total of 2,350,000 shares. Based on an average daily volume of 252,300 shares, the days-to-cover ratio is currently 8.5 days.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of the company's stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total transaction of $418,425.00. Following the transaction, the chief financial officer now owns 154,468 shares in the company, valued at approximately $8,617,769.72. This represents a 4.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Nikhil Lalwani sold 33,481 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the sale, the chief executive officer now owns 370,378 shares of the company's stock, valued at $21,478,220.22. The trade was a 8.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 42,381 shares of company stock valued at $2,441,556 in the last quarter. 12.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in ANI Pharmaceuticals by 24.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company's stock worth $177,000 after purchasing an additional 579 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of ANI Pharmaceuticals in the second quarter worth about $207,000. HighTower Advisors LLC acquired a new position in ANI Pharmaceuticals during the third quarter worth about $222,000. Profund Advisors LLC acquired a new position in ANI Pharmaceuticals during the second quarter worth about $225,000. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in ANI Pharmaceuticals during the 2nd quarter valued at about $228,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Price Performance

Shares of ANIP stock traded up $0.96 during trading hours on Friday, hitting $58.46. 302,520 shares of the company's stock were exchanged, compared to its average volume of 215,598. ANI Pharmaceuticals has a fifty-two week low of $52.50 and a fifty-two week high of $70.81. The firm has a market cap of $1.23 billion, a P/E ratio of -106.29 and a beta of 0.73. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The firm has a 50 day moving average of $56.36 and a two-hundred day moving average of $58.84.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, topping analysts' consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company had revenue of $148.30 million during the quarter, compared to analysts' expectations of $144.37 million. During the same period in the prior year, the business posted $1.05 earnings per share. The firm's revenue for the quarter was up 12.5% on a year-over-year basis. Sell-side analysts forecast that ANI Pharmaceuticals will post 3.87 EPS for the current year.

Wall Street Analyst Weigh In

ANIP has been the subject of a number of research reports. Leerink Partners started coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an "outperform" rating and a $80.00 price target for the company. Truist Financial raised their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a "hold" rating in a report on Tuesday, October 22nd. HC Wainwright reaffirmed a "buy" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Leerink Partnrs upgraded ANI Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, December 11th. Finally, Piper Sandler started coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an "overweight" rating and a $68.00 target price on the stock. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $77.71.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.